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Abstract
Background: GW/P bodies are cytoplasmic ribonucleoprotein-rich foci involved in microRNA (miRNA)-mediated messenger
RNA (mRNA) silencing and degradation. The mRNA regulatory functions within GW/P bodies are mediated by GW182 and its
binding partner hAgo2 that bind miRNA in the RNA-induced silencing complex (RISC). To date there are no published
reports of the profile of miRNA and mRNA targeted to the RISC or a comparison of the RISC-specific miRNA/mRNA profile
differences in malignant and non-malignant cells.
Methodology/Principal Findings: RISC mRNA and miRNA components were profiled by microarray analysis of malignant
human U-87 astrocytoma cells and its non-malignant counterpart, primary human astrocytes. Total cell RNA as well as RNA
from immunoprecipitated RISC was analyzed. The novel findings were fourfold: (1) miRNAs were highly enriched in
astrocyte RISC compared to U-87 astrocytoma RISC, (2) astrocytoma and primary astrocyte cells each contained unique RISC
miRNA profiles as compared to their respective cellular miRNA profiles, (3) miR-195, 10b, 29b, 19b, 34a and 455-3p levels
were increased and the miR-181b level was decreased in U-87 astrocytoma RISC as compared to astrocyte RISC, and (4) the
RISC contained decreased levels of mRNAs in primary astrocyte and U-87 astrocytoma cells.
Conclusions/Significance: The observation that miR-34a and miR-195 levels were increased in the RISC of U-87 astrocytoma
cells suggests an oncogenic role for these miRNAs. Differential regulation of mRNAs by specific miRNAs is evidenced by the
observation that three miR34a-targeted mRNAs and two miR-195-targeted mRNAs were downregulated while one miR-195-
targeted mRNA was upregulated. Biological pathway analysis of RISC mRNA components suggests that the RISC plays a
pivotal role in malignancy and other conditions. This study points to the importance of the RISC and ultimately GW/P body
composition and function in miRNA and mRNA deregulation in astrocytoma cells and possibly in other malignancies.
Citation: Moser JJ, Fritzler MJ (2010) The MicroRNA and MessengerRNA Profile of the RNA-Induced Silencing Complex in Human Primary Astrocyte and
Astrocytoma Cells. PLoS ONE 5(10): e13445. doi:10.1371/journal.pone.0013445
Editor: Joseph Najbauer, City of Hope National Medical Center, United States of America
Received May 1, 2010; Accepted September 14, 2010; Published October 18, 2010
Copyright:  2010 Moser, Fritzler. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a grant in aid (#MOP-57674) from the Canadian Institutes for Health Research and an anonymous donor. JJM is
supported by a Canadian Institute for Health Research Doctoral Research Award in the Area of Clinical Research and by an Alberta Heritage Foundation for
Medical Research Studentship Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fritzler@ucalgary.ca
Introduction
GW bodies (GWB, glycine- and tryptophan-rich cytoplasmic
processing bodies; also known as mammalian processing (P) bodies
or Dcp containing bodies, hereafter referred to as GW/P bodies)
are cytoplasmic foci in mammalian cells enriched in the GW182
protein, which is characterized by multiple glycine (G) and
tryptophan (W) repeats and a carboxyl terminal classical RNA
binding domain [1]. GW/P bodies have been shown to provide
the appropriate microenvironment for the RNA induced silencing
complex (RISC) and critical steps in the RNA interference (RNAi)
pathway [2,3]. Key components of GW/P bodies include Dicer,
human Argonaute 2 (hAgo2), and microRNAs (miRNA) (reviewed
in [4–7]). In addition, GW182 co-localizes with 59R39 mRNA
decay factors, CCR4, Dcp1, LSm4 and XRN1 [8–11] implicating
GW/P bodies as sites for messenger RNA (mRNA) processing and
degradation [5,12]. It is currently thought that silencing and
degrading factors are partitioned to GW/P bodies to increase the
efficiency of post-transcriptional regulation and to prevent the
inadvertent degradation of functional mRNA [13].
RNAi is the key pathway involved in the post-transcriptional
silencing of .50% of all mRNAs in cells and tissues from a variety
of organisms [14]. RNAi is mediated by endogenous double-
stranded RNA (dsRNA) precursors termed pre-miRNA that are
rapidly processed into miRNA duplexes of 18–22 nucleotides in
length by Dicer, a dsRNA-specific endonuclease [3]. These small
RNA duplexes are then incorporated into the RISC where the
passenger miRNA strand is dissociated by cleavage, degradation
or a bypass mechanism [15]. The remaining guide miRNA strand
subsequently activates the RISC by interacting with hAgo2
[16,17]. The RISC then recruits one or more heteromeric protein
complexes (e.g. GW182 and RCK/p54) to associate with the
mRNA leading to the formation of GW/P bodies. Depending on
the degree of complementarity between the guide-strand miRNA
and its target mRNA, the augmented RISC then initiates post-
transcriptional inhibition of gene expression through translational
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predicted to regulate hundreds of different target mRNAs while a
single mRNA has the potential to be regulated by dozens of
different miRNAs. GW/P bodies are formed in response to RNA-
mediated gene silencing [19,20] and are regarded as sites for
miRNA-mediated mRNA silencing [4,9], although some studies
have shown that the process of active RNAi can occur in the
absence of conventional microscopically visible GW/P bodies
[9,21]. Further, GW/P body protein components and binding
partners, GW182 and hAgo2, are co-factors in miRNA-mediated
translational repression and mRNA degradation [22] whereby the
C-terminal domain of GW182 is essential for miRNA function
[23], the RRM domain of GW182 has been shown to contribute
to miRNA-mediated silencing of mRNA [24] and the C-terminal
domain of hAgo2 must bind to the GW-rich regions of GW182 to
mediate silencing [25].
To date, miRNA have been shown to have an effect on the
development of many cancers [26–29] and it is now understood
that greater than half of the annotated human miRNA genes are
located in chromosomal regions frequently displaying amplifica-
tion, deletion, or translocation in human cancers [30]. In cycling/
proliferating cells (S/G2), such as cancer cells, miRNAs are
generally thought to repress mRNA translation [31]. In addition,
microRNAs are aberrantly expressed in a wide variety of human
cancers, including but not limited to those originating in ovarian,
breast, lung, gastrointestinal and brain tissues where they are
thought to play important roles by regulating the expression of
various oncogenes and tumor suppressors [28,32–37]. When
miRNAs are downregulated, they themselves can act as tumor
suppressors [38] or, when overexpressed, act as oncogenes
(referred to as oncomirs) [26,39,40] possibly through dysregulation
of the cell cycle leading to the formation of tumors.
Of more relevance to the current study, emerging evidence has
demonstrated that distinct patterns of microRNA expression were
found in glioblastomas and indicated that microRNAs play key
roles in maintaining malignant characteristics of stem cell
behavior, cell proliferation and invasion, and angiogenesis
(reviewed in [41]). For example, recent studies have shown that
miRNA-451 regulated signaling is a key in stress adaptation of
glioma cells [42] and dicer-regulated miRNAs-222 and -339
promote resistance to cytotoxic T-lymphocytes by down-regulat-
ing ICAM-1 [43]. Other evidence has demonstrated that
p27(Kip1) is a direct target for miRNAs 221 and 222, and may
promote aggressive growth characteristics of glioblastomas [44],
and miR-26a-mediated PTEN repression in a murine glioma
model enhanced de novo tumor formation and indicates a new
epigenetic mechanism for PTEN regulation in gliomas [45].
In this study, we used miRNA microarray and gene expression
microarray analyses to identify for the first time the miRNA and
mRNA components of the RISC in U-87 astrocytoma cells and
primary human astrocytes as compared to the global cellular
miRNA and mRNA in these cells. We found that miRNAs are
highly enriched in primary astrocyte RISC compared to U-87
astrocytoma RISC and that both cell lines contain unique RISC
miRNA profiles compared to their respective global cellular
miRNA. Specifically, U-87 astrocytoma RISC and primary
astrocyte RISC share some common miRNAs but also contain
their own unique subset of miRNAs. Further, RISC were found to
contain mostly downregulated mRNAs in both primary astrocyte
and U-87 astrocytoma cells. Taken together, our data suggest that
RISC miRNA and mRNA components are different from the
miRNA/mRNA profile of the global cellular milieu and key
differences between malignant and non-malignant cells may point
to novel diagnostic and therapeutic interventions.
Materials and Methods
Cells
Primary human cerebral cortex astrocyte cells (used between
passages 4–6, cat# 1800, ScienCell Research Laboratories,
Carlsbad, CA) were cultured under 5% CO2 in astrocyte medium
containing 2% fetal bovine serum, 1% astrocyte growth
supplement and 1% penicillin/streptomycin (ScienCell Research
Laboratories). Adherent human U-87 MG astrocytoma/glioblas-
toma cells (used between passages 18–22, cat# HTB-14,
American Type Culture Collection (ATCC), Rockville, MD) were
cultured under 5% CO2 in DMEM F12+1% L-glutamine (2 mM)
(Cambrex, Walkersville, MD) supplemented with 10% fetal bovine
serum (Gibco, Burlington, ON, Canada), 1% penicillin-strepto-
mycin (Gibco), 1% sodium pyruvate (1 mM) (Gibco) and 1% non-
essential amino acids (0.1 mM) (Gibco) at 37uC.
Ribonucleoprotein (RNP) Lysate Preparation
Primary astrocytes and U-87 astrocytoma cells were cultured as
described above in multiple 150 cm
2 tissue culture flasks,
harvested, washed in sterile RNase-free ice-cold phosphate
buffered saline (PBS: Ambion, Streetsville, ON, Canada), pooled
and pelleted by centrifugation at 196 g for 5 min at 4uCa s
previously described in detail [46]. PBS was aspirated from the cell
pellets and 1 equal volume of freshly prepared RNase-free ice-cold
polysome lysis buffer (10 mM HEPES pH 7.0, 100 mM KCl,
5 mM MgCl2, 25 mM EDTA pH 8.0, 0.5% IGEPAL, complete
EDTA-free protease inhibitors, 2 mM DTT, 50 U/ml RNase
OUT, 50 U/ml Superase IN) was added to the cell pellets [47].
Whole cell RNP lysates were vortexed, set on ice for 3 minutes and
then transferred to 280uC until use. To isolate the cellular RNP
proteins, the lysates were thawed on ice, sheared by passing them
through a syringe fitted with a 21G 1.5-inch needle and
centrifuged in a tabletop microfuge at 16,000 g for 10 min at
4uC [11,46]. The supernatant was removed, transferred to a new
centrifuge tube and re-centrifuged at 16,000 g for 10 min at 4uCt o
facilitate removal of the lipid layer overlying the supernatant. The
protein concentration in the cellular RNP lysate was quantitated
using a NanoVue spectrophotometer (GE Healthcare Life
Sciences, Baie d’Urfe, QC, Canada) and stored at 280uC. The
protein concentration of the cytoplasmic RNP lysates was 12 mg/
ml for primary astrocytes and 11 mg/ml for U-87 astrocytoma.
RISC RNA Immunoprecipitation (RISC-RIP)
Human serum 18033 (Mitogen Advanced Diagnostics Labora-
tory, Calgary, AB), was used as the source of antibodies that were
covalently coupled to protein A-Sepharose beads as previously
described [11,46,48]. We have previously shown that human
serum 18033 immunoprecipitated both GW182 and hAgo2
proteins [46]. Prior to immunoprecipitation (IP), 150 ml of the
antibody-coupled protein A-Sepharose beads for each IP reaction
was washed five times with NT2 buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM MgCl2, 0.05% IGEPAL) at room
temperature. Washed antibody-coupled beads were resuspended
in 1000 ml of freshly prepared ice-cold NET2F buffer (850 ml NT2
buffer, 10 ml 0.1 M DTT, 30 ml 0.5 M EDTA pH 8.0, 50 mlo f
50 mg/ml ultrapure bovine serum albumin, 5 ml RNase OUT,
5 ml Superase IN) and mixed by inversion. Immunoprecipitation
of the RISC-RNP complexes was accomplished by adding 200 ml
of the cellular RNP lysates to the antibody-coupled beads in
NET2F buffer. IP reactions were incubated overnight at 4uCo na
rotator. The beads were then centrifuged at 82 g for 30 seconds at
4uC, the supernatant removed and the RISC-RNP complex-
antibody-beads were washed six times in 1 ml of ice-cold NT2
miRNA and mRNA in Astrocytoma
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beads by SDS-TE heat denaturation by resuspension of washed
beads in 100 ml NET2F buffer and 100 ml of SDS-TE buffer
(20 mM Tris-HCl pH 7.5, 2 mM EDTA pH 8.0, 2% SDS) and
incubation at 55uC for 30 min [47]. Total RNA enriched in small
RNAs was isolated from the RISC-RNP complex using the
mirVana kit (Ambion) according to the procedures outlined in the
manufacturer’s protocol. RNA samples were stored at 280uC
until required for analysis. The total RNA concentration of the
RISC-RNP complex was 0.108 mg/ml for primary astrocytes and
0.318 mg/ml for U-87 astrocytoma.
mParaflo MicroRNA Microarray Assay
Microarray assays of global miRNA and RISC-immunoprecip-
itated miRNA in primary human astrocytes and U-87 astrocytoma
cells was outsourced to LC Sciences (Houston, TX). To isolate
global miRNA, total RNA was isolated from primary human
astrocytes (ScienCell) and U-87 astrocytoma cells (ATCC) using
the mirVana kit (Ambion). The global total RNA concentration
was 4.10 mg/ml for primary astrocytes and 2.49 mg/ml for U-87
astrocytoma cells. RISC-specific total RNA was isolated as
described above and RNA integrity was assessed with an Agilent
Bioanalyzer 2100 (Foster City, CA). The microarray assay was
performed using samples containing 5 mg total RNA, which were
fractionated using a YM-100 Microcon centrifugal filter (Milli-
pore, Billerica, MA) to isolate small RNAs (,300 nt). Small RNAs
were 39-extended with a poly(A) tail using poly(A) polymerase. An
oligonucleotide tag was then ligated to the poly(A) tail for later
fluorescent dye staining with Cy5.
Hybridizations were performed overnight on a mParaflo
microfluidic chip using a micro-circulation pump (Atactic
Technologies, Houston, TX) [49]. Each detection probe on the
microfluidic chip consisted of a chemically modified nucleotide
coding segment complementary to 6211 target human miRNAs
(Sanger miRBase version 11, http://microrna.sanger.ac.uk/
sequences/) or control RNAs (array hybridization controls and
single-base mismatch targets), and a polyethylene glycol spacer
segment to extend the coding segment away from the substrate.
The detection probes were made by in situ synthesis using
photogenerated reagent chemistry and were replicated seven
times within each microarray chip [50]. The hybridization melting
temperatures of the probes were balanced by chemical modifica-
tions of the detection probes. Hybridization was performed at
34uC using 100 mL of 6xSSPE buffer (0.90 M NaCl, 60 mM
Na2HPO4, 6 mM EDTA pH 6.8) containing 25% formamide.
After washing, the hybridized fluorescent Cy5 signals were
detected with a laser scanner (GenePix 4000B, Molecular Devices,
Sunnyvale, CA) and digitized by Array-Pro image analysis
software (Media Cybernetics, Bethesda, MD).
Data were further processed by subtracting the background
followed by signal normalization with a LOWESS (locally weighted
regression) filter [51]. For a miRNA transcript to be classified as
reliably detectable, it had to satisfy the following criteria: overall
signal intensity .36 background standard deviation, spot coeffi-
cient of variation ,0.5, and .50% of the repeated probes had
signal intensities above detection level. The data were log2
transformed and the p-values of the t-test were calculated.
Differentially detected miRNA signals with a p value of less than
0.01 were considered significant (p,0.01). Heat maps were
generated for the differentially expressed miRNAs with p,0.01.
Gene expression microarray
Gene expression microarray analyses of global mRNA and
RISC-immunoprecipitated mRNA in primary human astrocytes
and U-87 astrocytoma cells were outsourced to LC Sciences who
are partnered with an AffymetrixH Authorized Service Provider,
SeqWright DNA Technology Services (Houston, TX). Global and
RISC-RNP enriched total RNA were isolated as described above
and RNA integrity was assessed by an Agilent Bioanalyzer 2100
(Foster City, CA). Affymetrix’s GeneChip IVT Express kit was
used for cDNA synthesis and in vitro transcription. The gene
expression microarray assay was performed using a 5 mg total
RNA sample on an Affymetrix Human Genome U133A 2.0 Array
which analyzes the expression level of 18,400 transcripts and
variants, including 14,500 well-characterized human genes (Affyme-
trix, Santa Clara, CA). All procedures and analyses were performed
according to the protocol outlined in detail in the GeneChipH
Expression Analysis Technical Manual (Affymetrix, http://www.
affymetrix.com/support/downloads/manuals/expression_analysis_
technical_manual.pdf). Multi-chip expression intensity normaliza-
tion was performed for all 4 samples on gene expression chips using
the robustmultichip average (RMA)algorithm[52],which consisted
of three steps: background correction, quantile normalization (each
performed at the individual probe level), and robust linear model fit
using log-transformed intensities (at the probe set level). RMA
normalization was used because multiple chips were compared and
also because RMA methods allow for better detection of low-
abundance genes, which include many genes of interest, such as
transcription factors, and signalling proteins. The overall selection
criteria were based on expression values larger than a threshold 3.5
in more than 50% of samples.
Data Availability
The miRNA and mRNA microarray data generated by this
study are available in the NCBI Gene Expression Omnibus (GEO)
as series accession identifier GSE21514.
Functional Network Analysis
Functional profiling was performed by employing the compu-
tational gene network prediction tool Ingenuity Pathway Analysis
version 8.5 (IPA, IngenuityH Systems; http://www.ingenuity.com)
on all significantly expressed (p,0.01) miRNAs with log2 fold
change greater than or equal to 2 and mRNAs with a log2 fold
change greater than or equal to 2.5. For biological pathway
connections in U-87 astrocytoma RISC, miRNAs with a log2 fold
change greater than or equal to 3 and mRNAs with a log2 fold
change greater than or equal to 2 were used. IPA mapped the
uploaded microarray datasets into a global molecular network
developed from a literature-supported Ingenuity Pathways Knowl-
edge Base, and then generated networks that represent the
molecular relationships between miRNA and mRNA. Canonical
pathways were selected and overlayed onto the biological pathway
based on known biological significance from the most highly
overlapping pathways. MRNAs and miRNAs without connections
to other molecules or pathways were removed from the final
figure. The biological functions significantly associated with the
genes in the networks are provided by the Ingenuity Pathways
Knowledge Base and scored employing Fischer’s exact test with a
p,0.01.
cDNA Synthesis and Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
Global and RISC-RNP-enriched total RNA was extracted and
quantitated as described above. Poly-A tailing of the miRNA in
the total RNA sample and cDNA synthesis was performed using
the NCode VILO miRNA cDNA synthesis kit (Invitrogen,
miRNA and mRNA in Astrocytoma
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instructions. In brief, 1 mg of total RNA was added to 4 mlo f
5X Reaction Mix and 2 ml of 10X SuperScript Enzyme mix up to
a total volume of 20 ml. Reactions were mixed by pipeting and
incubated at 37uC for60 min. The reactions were terminated at
95uC for 5 min and stored at 220uC until use in the qRT-PCR
reaction. The cDNA was diluted with nuclease free water to give a
DNA concentration of ,375 ng/ml and qRT-PCR reactions
performed using the EXPRESS SYBR GreenER Universal qRT-
PCR kit (Invitrogen). Each 20 ml qRT-PCR reaction contained
10 ml of EXPRESS SYBR GreenER qPCR SuperMix Universal,
0.4 mlo f1 0 mM miRNA-specific forward primer or 10 mM
mRNA-specific forward primer (listed in Table S1), 0.4 mlo f
10 mM Universal reverse qPCR primer or 10 mM mRNA-specific
reverse primer (listed in Table S1), 1 ml of 1:10,000 diluted
fluorescein calibration dye and 1 ml of diluted cDNA up to a final
volume of 20 ml with nuclease-free water. The qRT-PCR
reactions were performed in triplicate with a BioRad MyiQ
Single Color Real-Time PCR detection system iCycler pro-
grammed as follows: 1 cycle at 50uC for 2 min for UDG
incubation; 1 cycle at 95uC for 2 min; 40 cycles of 95uC for 15
seconds and 60uC for 1 min, followed by a melting curve analysis
at 95uC for 1 min and 60uC for 1 min and 10 sec. The cycle
threshold (Ct) values, corresponding to the PCR cycle number at
which fluorescence emission reaches a threshold above baseline
emission, were determined and the mRNA and miRNA levels
calculated using the comparative 2
-DDCt method. A comparison of
the relative mean fold increase in gene expression between two
housekeeping genes, beta-actin and 80S RNA was examined to
determine the most stable housekeeping gene. Due to smaller
standard deviations between the 2
-DDCt over 3 independent
experiments, the beta-actin gene was used as the reference marker
for gene expression normalization. For analysis of miRNA by
qRT-PCR, RNU44 and RNU6B controls were examined to
determine the most stable small RNA endogenous control. Due to
smaller standard deviations between the 2
-DDCt values over 3
independent experiments, RNU6B was used as the reference
marker for miRNA expression normalization.
Results and Discussion
miRNAs are highly enriched in primary astrocyte RISC
compared to U-87 astrocytoma RISC
MiRNA microarray analysis was undertaken to examine the
spectrum of cellular miRNAs in primary human astrocyte and
human U-87 astrocytoma cells and then compared to those
associated with the RISC of the respective cells. Several key
observations were made from the examination of the four miRNA
microarray data domains. First, comparison of U-87 astrocytoma
cell and primary astrocyte global miRNA at equivalent RNA
concentrations showed that the signal intensity of global miRNAs
in the U-87 astrocytoma cells were generally increased compared
to primary astrocytes (Figure 1, top and bottom left) suggesting
that astrocytoma cells may have an increased number of individual
miRNAs compared to the number in normal astrocytes. In
addition, the global miRNA profile of astrocytoma cells was
enriched in, and contained a greater variety of, miRNA than
primary astrocytes. Second, comparison of global miRNA and
RISC-immunoprecipitated (RISC-IP) miRNA in astrocytoma cells
demonstrated that the signal intensity of the same miRNA species
did not vary between the RISC-enriched population and that of
the global miRNA population (Figure 1, top left and right)
suggesting that astrocytoma cell RISC are not as highly enriched
in specific miRNAs and display the same relative signal intensity
and contain many of the same miRNAs as astrocytoma cells.
Third, comparison of global miRNA and RISC-IP miRNA
revealed that the signal intensity and number of miRNAs of the
RISC-IP miRNA was remarkably increased in primary astrocytes
Figure 1. MiRNA microarray images of global and RISC-
immunoprecipitated (RISC-IP) miRNA from human U-87 astro-
cytoma and primary human astrocyte cells. The representative
chip images are displayed in pseudo colors to expand the visual
dynamic range. As signal intensity increases from 1 to 65,535, the
corresponding color changes from blue to green, to yellow and to red.
doi:10.1371/journal.pone.0013445.g001
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PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13445Figure 2. RISC-IP miRNA expression compared to global miRNA expression in primary human astrocytes. (A) MiRNAs with a log2 fold
change .2( p ,0.01). MiRNAs with a positive fold change were increased in the RISC compared to the global cellular milieu in primary astrocytes and
miRNAs with a negative fold change are decreased in RISC compared to the global cellular milieu in primary astrocytes. (B) Hierarchical cluster
heatmap showing all significantly expressed miRNAs (p,0.01) in four independent samples/cell types. Each row shows the relative expression level
for a single miRNA and each column shows the expression level for a single sample. The red or green color indicates relative high or low expression,
respectively. (C) Disease/disorders associated with the miRNAs differentially expressed in RISC compared to the global cellular milieu of primary
astrocytes with a Fisher’s exact test p-value threshold set at 0.01 (yellow threshold line) using Ingenuity Pathway Analysis software.
doi:10.1371/journal.pone.0013445.g002
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13445Figure 3. RISC-IP miRNA expression compared to global miRNA expression in human U-87 astrocytoma cells. (A) MiRNAs with a log2
fold change .2( p ,0.01). MiRNAs with a positive fold change are increased in RISC compared to the global cellular milieu in astrocytoma cells and
miRNAs with a negative fold change are decreased in RISC compared to the global cellular milieu in astrocytoma cells. (B) Hierarchical cluster
heatmap showing all significantly expressed miRNAs (p,0.01) in four independent samples/cell type. Each row shows the relative expression level for
a single miRNA and each column shows the expression level for a single sample. The red or green color indicates relative high or low expression,
respectively. (C) Disease/disorders associated with the miRNAs differentially expressed in RISC compared to the global cellular milieu of U-87
astrocytoma cells with a Fisher’s exact test p-value threshold set at 0.01 (yellow threshold line) using IPA software. (D) MiRNAs in RISC compared to
the global cellular fraction in U-87 astrocytoma cells. U-87 astrocytoma cell miRNA expression was normalized to primary astrocytes miRNA
expression. MiRNAs displayed have a log2 fold change .3. Green and red arrows indicate decreased and increased miRNA levels respectively.
doi:10.1371/journal.pone.0013445.g003
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13445Figure 4. MiRNA microarray validation with qRT-PCR analysis for (A) global miRNA and (B) RISC-specific miRNA. Nine random miRNAs
were selected from the miRNA microarray datasets and examined by qRT-PCR. Fold change from the miRNA microarray are given by log2 values (left
y-axis, light grey bars). Fold change from the qRT-PCR was determined using the 2
-DDCt method and all miRNA expression values were normalized to
the RNU6B endogenous control (right y-axis, dark grey bars). Error bars represent the standard deviation of the mean (SD). Note: only the general
trend of up-regulation and down-regulation can be compared but the fold change (y-axis) cannot be directly compared between assays due to
differences in calculation methods.
doi:10.1371/journal.pone.0013445.g004
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13445Figure 5. RISC-IP miRNA expression in human U-87 astrocytoma cells compared to primary human astrocytes. (A) MiRNAs with a log2
fold change .2( p ,0.01). MiRNAs with a positive fold change are increased in RISC-IP astrocytoma cells compared to RISC-IP astrocytes and miRNAs
with a negative fold change are decreased in RISC-IP astrocytoma cells compared to RISC-IP astrocytes. (B) Hierarchical cluster heatmap showing all
significantly expressed miRNAs (p,0.01) in four independent samples/cell type. Each row shows the relative expression level for a single miRNA and
each column shows the expression level for a single sample. The red or green color indicates relative high or low expression, respectively. (C) Disease/
disorders and (D) molecular and cellular functions associated with the miRNAs differentially expressed in RISC of U-87 astrocytoma cells compared to
primary astrocytes with a Fisher’s exact test p-value threshold set at 0.01 (yellow threshold line) using IPA software.
doi:10.1371/journal.pone.0013445.g005
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bottom left and right), suggesting that a greater number of
miRNAs are enriched in primary astrocyte RISCs. Fourth,
comparison of astrocytoma and astrocyte RISC-IP miRNA
indicated that the number of miRNA species and the signal
intensity of miRNAs present in the primary astrocyte RISC-IP
were increased (Figure 1, right top and bottom) indicating that
primary astrocyte RISC may be enriched in a relatively more
diverse population of miRNAs and contain a greater number of
individual miRNAs than U-87 astrocytoma RISC. These results
suggested that depletion or deregulation of the specific miRNA
population in RISC could potentially play an important role in the
maintenance of the malignant state.
The signal probe intensity plot comparing the RISC-IP
miRNAs to global miRNAs for U-87 astrocytoma cells and
primary astrocytes showed many miRNAs that were equally
expressed in cell fractions from both cell types (Figure S1).
However, in both cell types, there was a subset of miRNAs that
had higher signal intensity in RISC (Figure S1) and lower signal
intensity in RISC (Figure S1). Furthermore, both cell types had
their own unique miRNA signal distribution pattern suggesting
that each cell type had a unique RISC miRNA profile.
RISC miRNA profile in primary human astrocytes
Primary astrocyte RISC contained a unique subset of
significantly expressed (p,0.01) miRNAs when normalized to
the expression levels of global astrocyte miRNAs (Figure 2). In this
study, all significantly expressed miRNAs with a log2 fold change
.62 and a p,0.01 were regarded as miRNAs with significantly
different expression. In astrocyte RISC, 13 miRNAs had a log2
fold change greater or equal to 62 (Figure 2A) and of these, miR-
424, miR-22, 125a-5p, 335 and 26b were increased by .2 fold
change compared to global miRNA levels (Figure 2A). Notably,
miR-424 was increased in RISC by ,5 fold. MiR-9*, 1280, 9, 720
and 1308 were all decreased in RISC with a log2 fold change
below 23 and miR-455-3p, 155 and 923 were decreased between
22 and 23 fold (Figure 2A). Only 13 miRNAs had a fold change
.62, yet many RISC-IP miRNA expression levels could still
considered to be significantly different from global miRNA
expression levels (p,0.01) (Figure 2B). Significant miRNA
expression levels for 4 independent RISC-IP and global samples
from primary astrocytes were plotted on a hierarchical clustered
heatmap, illustrating that 60% of miRNAs (81 of 135) were
increased while the remaining 40% (51/135) were decreased in
RISC in primary astrocytes compared to the global cellular
miRNA pool (Figure 2B).
Ingenuity Pathway Analysis (IPA) of the 13 key miRNAs with a
log2 fold change .62 in astrocyte RISC predicted that these
miRNAs were predominantly associated with genetic disorders
and musculoskeletal disorders, however, these specific miRNAs
have also been predicted to associate with inflammatory disease,
cancer and reproductive system disease (Figure 2C, threshold set
at p,0.01 using Fisher’s exact test).
RISC miRNA profile in human U-87 astrocytoma cells
U-87 astrocytoma cell RISC also contained a unique subset of
miRNAs when normalized to the global U-87 astrocytoma cell
miRNA levels (Figure 3). As above, miRNAs having levels log2
fold .62 and a p,0.01 were reported as miRNAs with key
differences. In U-87 astrocytoma RISC, only 6 miRNAs had a
log2 fold change .62 (Figure 3A). Of these miRNAs, only miR-
19b was increased by .62 fold compared to global miRNA levels
(Figure 3A). MiR-9, 29c, 768-5p and 1308 were all decreased in
RISC with a log2 fold change below 23 and miR-1280 was
decreased between 22 and 23 fold (Figure 3A). Of interest, in
both U-87 astrocytoma and primary astrocyte RISC, miR-9 and
miR-1308 were both decreased with the same relative log2 fold
change value (Figure 2 and 3). Only 6 miRNAs had a fold change
.62, yet many U-87 astrocytoma RISC-IP miRNA levels were
still considered to be significantly different from global miRNA
levels (p,0.01) (Figure 3B). Significant miRNA levels for 4
independent RISC-IP and global samples from U-87 astrocytoma
cells were plotted on a hierarchical clustered heat map and show
that 52.8% of miRNAs (47 of 89) were increased in U-87
astrocytoma cells RISC as compared to the global cellular miRNA
pool (Figure 3B). The remaining 47.2% of miRNAs (42 of 89) were
decreased in U-87 astrocytoma RISC (Figure 3B). Of note, U-87
astrocytoma RISC contained 46 fewer miRNA species (p,0.01)
than primary astrocyte RISC (Figure 2B compared to Figure 3B).
In addition, comparison of the population of miRNAs that were
increased, U-87 astrocytoma RISC contained 12.8% fewer
miRNAs as compared to primary astrocyte RISC (compare
Figure 2B and Figure 3B).
IPA of the 6 key miRNAs with a log2 fold change .62 in U-87
astrocytoma RISC predicted that these miRNAs may be
predominantly associated with cancer, however, these specific
miRNAs have also been predicted to be associated with
inflammatory diseases and genetic disorders (Figure 3C, threshold
set at p,0.01 using Fisher’s exact test). Interestingly, U-87
astrocytoma RISC miRNAs were predicted to be predominately
associated with cancer (Figure 3C), whereas in primary astrocytes,
RISC miRNAs were less associated with cancer and more with
genetic disorders (Figure 2C). The –log (p-value) scale differs
Table 1. Significantly expressed (p,0.01) RISC-
immunoprecipitated miRNAs in human U-87 astrocytoma
cells compared to primary human astrocytes with log2.3.
ID Symbol Fold Change p-value
hsa-miR-195 MIR195 5.468 7.00E-07
hsa-miR-10b MIR10B 5.273 2.91E-05
hsa-miR-29b MIR29B 4.634 9.67E-07
hsa-miR-19b MIR19B 3.320 6.17E-05
hsa-miR-34a MIR34A 3.040 8.43E-09
hsa-miR-181b MIR181B 23.900 2.28E-06
doi:10.1371/journal.pone.0013445.t001
Table 2. Significantly expressed (p,0.01) global miRNAs in
human U-87 astrocytoma cells compared to primary human
astrocytes with log2.3.
ID Symbol Fold Change p-value
hsa-miR-29b MIR29B 6.214 3.52E-05
hsa-miR-29c MIR29C 6.171 7.99E-05
hsa-miR-195 MIR195 4.491 5.75E-08
hsa-miR-20b MIR20B 3.061 1.19E-07
hsa-miR-1280 MIR1280 23.122 1.24E-06
hsa-miR-720 MIR720 23.149 8.45E-08
hsa-miR-1826 MIR1826 23.206 2.11E-09
hsa-miR-31 MIR31 27.869 2.47E-03
doi:10.1371/journal.pone.0013445.t002
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for IPA analysis (i.e. 13 vs. 6), but functional trend analysis shows
that miRNAs associated with inflammatory disease appear to be
approximately the same for both U-87 astrocytoma cells and
primary astrocytes (compare Figure 2C and Figure 3C).
Upon normalization of significant (p,0.01) U-87 miRNA
microarray values to primary astrocyte miRNA microarray values,
RISC-specific miRNAs could be identified and separated from
miRNAs that were unique to the global cellular milieu (i.e. were
not a part of RISC) in U-87 astrocytoma cells (Figure 3D). Unique
to RISC in U-87 astrocytoma cells were miR10b, 19b, 34a and
181b. Of this U-87 astrocytoma RISC subset, all were increased
with the exception of miR-181b which was decreased when
compared to astrocytes (Figure 3D). MiRNAs not present in U-87
astrocytoma RISC included miR-1280, 1826, 31, 720, 20b and
29c all of which were decreased with the exception of miR-20b
and 29c which were increased when compared to astrocytes
(Figure 3D). MiR-195 and 29b were found in both U-87
astrocytoma RISC and in the cellular milieu and were both
increased but with different levels (Figure 3D). Global miR-195
was increased with a log2 fold of 4.491, a difference of 20.977
from RISC expression. On the other hand, global miR-29b was
Figure 6. Global mRNA levels to RISC-IP mRNA levels in U-87 astrocytoma and primary astrocytes. A hierarchical heatmap comparing
global mRNA levels to RISC-IP mRNA levels in U-87 astrocytoma and primary astrocytes. MRNAs included in the heatmap had a fold change .1.4 and
were significantly expressed (p,0.01).
doi:10.1371/journal.pone.0013445.g006
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expression, suggesting that miR-29b has a more significant
regulatory role in the global cellular fraction than in the RISC.
The global and RISC-IP miRNA microarray results were
subsequently validated by qRT-PCR with miRNA normalized to
the endogenous RNU6B control (Figure 4). A total of 18 miRNAs
were examined by qRT-PCR for global and RISC-IP miRNA in
U-87 astrocytoma cells as normalized to primary astrocytes
(Figure 4). The values of fold change cannot be directly compared
between microarray and qRT-PCR assays due to differences in
calculation methods (log2 for microarray and 2
-DDCt for qRT-
PCR), yet comparisons could be made based on the general trend
of increased or decreased levels (Figure 4). For global miRNA,
miR-29b, 29c, 195, 10b and 20b were increased in qRT-PCR
analyses and exhibited the same general trend as determined by
microarray analysis (Figure 4A). The trend was not as evident for
the decreased global miRNAs where there was slightly greater
variation in miR-181b, 1280 and 432 qRT-PCR and microarray
expression values; however miR-1826 levels coincided between
assays (Figure 4A). For RISC-IP miRNA, the trend is similar for
both microarray and qRT-PCR assays (Figure 4B).
Specific miRNA levels are different in U-87 astrocytoma
RISC compared to primary astrocyte RISC
Comparison of miRNA levels in RISC of U-87 astrocytoma and
primary astrocytes by microarray also showed that RISC miRNA
levels were cell type specific (Figure 5). As previously described, all
significantly (p,0.01) expressed miRNAs with a log2 fold change
.62 were denoted as miRNAs with key differences. Using cutoff,
U-87 astrocytoma RISC contain a higher number of increased
miRNA species compared to astrocyte RISC (Figure 5A). As such,
miR-195, 10b, 29b, 19b, 34a and 455-3p were all increased in U-
87 astrocytoma RISC as compared to primary astrocyte RISC
(Figure 5A). MiR-181b was decreased with a log2 fold change
.62 in U-87 astrocytoma RISC as compared to primary
astrocyte RISC (Figure 5A). Notably, 6 RISC-IP miRNAs had a
significant log2 fold change .63 (Figure 5A, Table 1). Only 7
miRNAs had a fold change .62, yet many U-87 astrocytoma
RISC-IP miRNA levels were still considered to be significantly
different from levels in primary astrocyte RISC-IP miRNA
(Figure 5B). When significant (p,0.01) miRNA levels for 4
independent U-87 astrocytoma and primary astrocyte RISC-IP
samples were plotted on a hierarchical clustered heatmap, 50.8%
of miRNAs (65 of 128) were increased in U-87 astrocytoma RISC
compared to astrocyte RISC (Figure 5B). The remaining 49.2% of
miRNAs (63 of 128) were decreased in U-87 astrocytoma RISC in
comparison to astrocyte RISC (Figure 5B).
These observations suggest U-87 astrocytoma cell RISC contain
specific miRNAs that could potentially target tumor suppressor
mRNA or act as oncogenes themselves resulting in increased
proliferation, decreased cell death and tumor formation. Indeed,
miR-19b located within the mir-17–19b-1 cluster has been shown
to function as an oncogene by targeting apoptotic factors that are
activated in response to MYC overexpression, thereby allowing
MYC to induce controlled cell proliferation [26]. In human
glioblastoma samples, miR-10b was increased whereas brain-
enriched miR-181b was decreased in human glioblastoma samples
and in 10 human glioblastoma cell lines one of which included U-
87 astrocytoma cells [53]. In support of increased miR-10b
expression in gliomablastomas, another study showed that miR-
10b was highly associated with higher grade gliomas suggesting
that miR-10b may play a role in tumor invasiveness [54]. Further,
miR-10b was also highly expressed in metastatic breast cancer
Table 3. RISC-immunoprecipitated mRNA compared to global cellular mRNA in U-87 astrocytoma cells and primary astrocytes
with a fold change . 61.8 (p,0.01).
Affymetrix ID Symbol Entrez Gene Name Fold Change Location Type(s)
235059_at RAB12 RAB12, member RAS oncogene family 1.850 Cytoplasm enzyme
226663_at ANKRD10 ankyrin repeat domain 10 21.820 Nucleus transcription regulator
227223_at RBM39 RNA binding motif protein 39 21.820 Nucleus transcription regulator
231735_s_at MALAT1 metastasis associated lung adenocarcinoma
transcript 1 (non-protein coding)
21.830 unknown other
210057_at SMG1 SMG1 homolog, phosphatidylinositol 3-kinase-
related kinase (C. elegans)
21.830 Cytoplasm kinase
239487_at FAM98A family with sequence similarity 98, member A 21.840 unknown other
242146_at SNRPA1 small nuclear ribonucleoprotein polypeptide A’ 21.860 Nucleus other
227062_at NEAT1 (includes
EG:283131)
nuclear paraspeckle assembly transcript 1
(non-protein coding)
21.890 unknown other
1560031_at FRMD4A FERM domain containing 4A 21.900 unknown other
242669_at UFM1 ubiquitin-fold modifier 1 21.900 Cytoplasm other
558080_s_at DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 21.910 Cytoplasm other
242121_at NCRNA00182 non-protein coding RNA 182 21.930 unknown other
210649_s_at ARID1A AT rich interactive domain 1A (SWI-like) 21.980 Nucleus transcription regulator
230270_at PRPF38B PRP38 pre-mRNA processing factor 38 (yeast)
domain containing B
22.050 unknown other
234989_at NEAT1 (includes
EG:283131)
nuclear paraspeckle assembly transcript 1
(non-protein coding)
22.100 unknown other
230494_at SLC20A1 solute carrier family 20 (phosphate transporter),
member 1
22.290 Plasma Membrane transporter
doi:10.1371/journal.pone.0013445.t003
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metastasis [55].
In contrast to our observation of miR-195 levels being increased
in U-87 astrocytoma RISC, miR-195 has been shown to be
downregulated in various cancer cells including hepatocellular
carcinoma [36,37,56]. MiR-195 was shown to play a fundamental
role in cell cycle regulation and tumorigenesis where overexpres-
sion repressed phosphorylation of rentioblastoma (Rb)-E2F
signalling downregulated mRNA targets such as cyclin D1,
CDK6 and E2F3, thus suggesting miR-195 as a potential target
for cancer therapy [57]. MiR-195 expression has not been
specifically reported in brain cancers to date. Our results show
miR-195 is in U-87 astrocytoma cell RISC as contrasted to
primary astrocyte RISC, suggesting that U-87 astrocytoma RISC
may be enriched in tumor suppressive miR-195 in an attempt to
regulate the cell cycle and cell proliferation.
In our study, miR-34a was upregulated in U-87 astrocytoma
RISC, however in other reports miR-34a was shown to be
downregulated in cancer cells and tumors including colon cancer,
leukemia, hepatocellular carcinoma and non-small cell lung cancer
[58–60]. MiR-34a has been extensively studied in cancer and
many studies point to miR-34a as a transcriptional target of p53
tumor suppressor whereby upregulation or activation of miR-34a
contributes to p53-mediated apoptosis and G1 cell cycle arrest
[61–63]. Other studies have shown that miR-34 overexpression
also takes place independent of p53 upregulation [64,65]. In
recent years, miR-34a has been found to affect tumor cell
apoptosis, senescence, proliferation and invasion [59,63,66–68]. In
addition, a few mRNA targets of miR-34a are oncogenes such as
MYC, CDK6, SIRT1 and c-Met [68–71]. In glioblastoma tumors,
miR-34a was generally downregulated but when overexpressed,
functioned to inhibit glioblastoma cell proliferation, survival,
migration and invasion by targeting c-Met and Notch [72,73].
MiR-34a is generally thought to be a tumor suppressor, however
in our study and others, it has been found to be upregulated in
several cancers including renal cell carcinoma [74], colon cancer
[67] and hepatocellular carcinoma [75].
The 7 key IPA miRNAs with a log2 fold change .62 in U-87
astrocytoma RISC compared to primary astrocyte RISC showed
these miRNAs are associated with many diseases/disorders and
have a role in specific molecular and cellular functions (Figure 5C,
5D). Specifically, U-87 astrocytoma RISC contain miRNAs that
play a predominant role in inflammatory disease, cancer and
genetic disorders and to a lesser extent in neurological disease and
connective tissue disorders (Figure 5C, threshold set at p,0.01). In
addition, U-87 astrocytoma RISC contain miRNAs that play a
role in cellular compromise, development and growth and
proliferation (Figure 5, threshold set at p,0.01 using Fisher’s
exact test). Not only are astrocytes important for neuronal survival
and function, they contribute to the formation and preservation of
a functional blood-brain barrier, control ionic and osmotic
homeostasis [76], and play a role in the development and
plasticity of the central nervous system by modifying the growth of
axons and dendrites and regulating synapse formation [77]. They
also play a central role in the control of the immune response and
surveillance in the central nervous system [78,79]. Indeed, our
Figure 7. (A) MRNA microarray validation with qRT-PCR analysis in grouped RISC-IP U-87 astrocytoma and primary astrocytes samples. Grouped
RISC-IP data were compared to the grouped global mRNA from U-87 astrocytoma and primary astrocytes samples. Eight mRNAs were selected from
the grouped mRNA microarray dataset and examined by qRT-PCR. Fold change from the mRNA microarray are given by log2 values (left y-axis, light
grey bars). Fold change from the qRT-PCR was determined using the 2
-DDCt method and all mRNA expression values were normalized to the beta-
actin endogenous control (right y-axis, dark grey bars). Error bars represent the standard deviation of the mean (SD). Importantly, the fold change (y-
axis) cannot be directly compared between assays due to differences in calculation methods, but the general trend of up-regulation and down-
regulation can be compared. (B) MRNAs in RISC compared to the global cellular milieu in U-87 astrocytoma cells. MRNA expression in U-87
astrocytoma cells were normalized to primary astrocytes mRNA expression. All mRNAs had a fold change .2.5 and were significantly expressed
(p,0.01). Green and red arrows indicate decreased and increased levels respectively.
doi:10.1371/journal.pone.0013445.g007
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regulate inflammatory and immune responses to a greater extent
than neurological processes suggests astrocytoma cells are
characterized by RISC-associated dysregulated immune surveil-
lance and inflammatory responses. Of interest, dicer-regulated
miRNAs-222 and -339 have been reported to promote resistance
to cytotoxic T-lymphocytes by down-regulating ICAM-1 [43].
A comparison of global miRNA expression between U-87
astrocytoma cells and primary astrocytes was not the primary focus
of this study, yet this data has been included for completeness
(Figure S2). In brief, there were 40 global miRNAs that had a log2
fold change greater than or equal to 2 in U-87 astrocytoma cells
when compared to primary astrocytes (Figure S2A) with 8 of these
global miRNAs having a significant log2 fold change .63 (Figure
S2A,Table2).Aswiththe celltypespecificRISC-IPmiRNAs,there
was a relatively equal representation of increased and decreased
miRNAs in the global cellular milieu of both cell types (Figure S2B).
IPA of the 40 key global miRNAs with a log2 fold change .62i n
U-87 astrocytoma cells compared to primary astrocytes showed
these miRNAs were predicted to be associated with the same, albeit
a higher number of diseases/disorders than those miRNAs that
were specifically within RISC (Figure S2C). Global miRNAs play a
role in cellular compromise, cellular development and cellular
growth and proliferation as do RISC miRNAs, however to a lesser
extent than RISC-specific miRNAs (Figure S2D).
RISC contain mostly decreased levels of mRNAs in
primary astrocytes and U-87 astrocytoma cells
When global and RISC-IP gene expression in U-87 astrocyto-
ma and primary astrocytes were analyzed on Affymetrix Human
Genome U133A 2.0 Arrays, a slight variation in the specific global
mRNA levels or RISC-IP mRNA levels between U-87 astrocy-
toma cells and primary astrocytes was observed. However, when
significant (p,0.01) cell-specific expression values with a fold
change .61.4 (using the RMA algorithm) were grouped into a
hierarchical clustered heat map of global versus RISC-IP sample
sets, a unique profile of RISC-specific increased and decreased
genes was observed (Figure 6). Relative to global gene expression,
U-87 astrocytoma and primary astrocyte RISC contained 93.9%
of mRNA that were significantly (p,0.01) decreased (92 of 98
total) and 6.1% of mRNA that were significantly (p,0.01)
increased (6 of 98 total) (Figure 6), suggesting that the majority
of mRNAs targeted to RISC are downregulated. Of the 98 genes
expressed, 64 could be mapped to known genes in the Entrez gene
database that encode enzymes, transcriptional regulators, trans-
porters and other proteins (Table 3).
The gene expression microarray results for RISC-IP (U-87
astrocytoma and primary astrocyte) were validated by qRT-PCR
with gene expression normalized to the beta-actin housekeeping
gene (Figure 7A). As above, fold change values cannot be directly
compared between microarray and qRT-PCR assays due to
Table 4. RISC-immunoprecipitated mRNA in human U-87 astrocytoma cells compared to RISC-immunoprecipitated mRNA in
primary human astrocytes with a fold change .62.6 (p,0.01).
Affymetrix ID Symbol Entrez Gene Name Fold Change Location Type(s)
243036_at CCDC30 coiled-coil domain containing 30 3.320 unknown other
206172_at IL13RA2 interleukin 13 receptor, alpha 2 3.140 Plasma Membrane transmembrane receptor
205767_at EREG epiregulin 3.100 Extracellular Space growth factor
207638_at PRSS7 protease, serine, 7 (enterokinase) 2.830 Extracellular Space peptidase
205681_at BCL2A1 BCL2-related protein A1 2.780 Cytoplasm other
205828_at MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 2.770 Extracellular Space peptidase
1558945_s_at CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A
subunit
2.660 Plasma Membrane ion channel
204971_at CSTA cystatin A (stefin A) 2.660 Cytoplasm other
205016_at TGFA transforming growth factor, alpha 2.660 Extracellular Space growth factor
217388_s_at KYNU kynureninase (L-kynurenine hydrolase) 2.650 Cytoplasm enzyme
1558846_at PNLIPRP3 pancreatic lipase-related protein 3 2.600 unknown other
219134_at ELTD1 EGF, latrophilin and seven transmembrane domain
containing 1
22.620 Plasma Membrane G-protein coupled
receptor
1553605_a_at ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 22.630 unknown transporter
244050_at PTPLAD2 protein tyrosine phosphatase-like A domain containing 2 22.650 unknown other
244741_s_at MGC9913 hypothetical protein MGC9913 22.700 unknown other
227971_at NRK Nik related kinase 22.760 unknown kinase
202409_at IGF2 insulin-like growth factor 2 (somatomedin A) 22.870 Extracellular Space growth factor
207173_x_at CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 22.900 Plasma Membrane other
232060_at ROR1 receptor tyrosine kinase-like orphan receptor 1 22.900 Plasma Membrane kinase
228979_at SFTA3 surfactant associated 3 22.940 unknown other
228335_at CLDN11 claudin 11 22.950 Plasma Membrane other
205907_s_at OMD osteomodulin 23.250 Extracellular Space other
213764_s_at MFAP5 microfibrillar associated protein 5 23.330 Extracellular Space other
201110_s_at THBS1 thrombospondin 1 23.710 Extracellular Space other
doi:10.1371/journal.pone.0013445.t004
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the RISC of U-87 astrocytoma cells compared to primary
astrocytes and the mRNA in the global cellular milieu of U-87
astrocytoma cells compared to primary astrocytes. Bar charts
display the relative number (-log(p-value)) of mRNAs with a fold change
.2.5 and were considered significant (p,0.01). RISC-IP mRNA were
indicated with dark blue bars and the global mRNA were indicated with
light blue bars. The threshold (yellow lines) were set at p,0.01 and
were calculated using Fischer’s exact p-value test using IPA software.
doi:10.1371/journal.pone.0013445.g008
Figure 9. Molecular and cellular functional assessment of the
mRNA in the RISC of U-87 astrocytoma cells compared to
primary astrocytes and the mRNA in the global cellular milieu
of U-87 astrocytoma cells compared to primary astrocytes. Bar
charts display the relative number (-log(p-value)) of mRNAs with a fold
change .2.5 and were considered significant (p,0.01). RISC-IP mRNA
were indicated with dark blue bars and the global mRNA were indicated
with light blue bars. The threshold (yellow lines) were set at p,0.01 and
were calculated using Fischer’s exact p-value test using IPA software.
doi:10.1371/journal.pone.0013445.g009
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-DDCt
for qRT-PCR), however comparisons could be made based on the
general trend (Figure 7A). The 6 mRNA cDNA examined by
qRT-PCR included RAB12, ITCH, GW2 (TNRC6B), MAP1B,
CEP350 and SNRPA1 (Figure 7A). In general, the qRT-PCR
results for each of these mRNA cDNA correlated with the
microarray results, whereby RAB12 and ITCH expression were
both increased in RISC and GW2, MAP1B, CEP350 and
SNRPA1 expression were decreased when compared to the global
cellular mRNA expression levels (Figure 7A).
There were many decreased mRNAs that were shared between
U-87 astrocytoma cells and primary astrocytes in RISC, as well as
differences in RISC-specific mRNA levels (Figure S3). Differences
in significant (p,0.01) mRNA levels between U-87 astrocytoma
and astrocytes were mapped onto a hierarchical clustered heatmap
with mRNAs that exhibited a fold change .62.3 (Figure S3,
Table 4). U-87 astrocytoma cell RISC contained 41 decreased
mRNAs and 30 increased mRNAs out of a total of 74 mRNAs as
compared to primary astrocytes (Figure S3) and include
transmembrane receptors, growth factors, peptidases, transcrip-
tion regulators, cytokines and other proteins as listed in Table 4.
Globally, there were also specific mRNA level differences between
U-87 astrocytoma cells and primary astrocytes (Figure S4, Table
S2). In brief, 71 mRNAs were decreased and 30 mRNAs were
increased in the global cellular fraction of U-87 astrocytoma cells
as compared to primary astrocytes (Figure S4, p,0.01, log2 fold
change .62.3) and include enzymes, peptidases, cytokines,
growth factors, G-protein coupled receptors, transcription regula-
tors and others (Table S2).
Comparison of mRNA levels in U-87 astrocytoma cell RISC
and the global cellular fraction as compared to primary astrocytes
provided a unique RISC mRNA profile, a unique global mRNA
profile and a list of mRNAs that are shared between RISC and the
global cellular milieu (Figure 7B). Overall, a greater number of
mRNA species were unique to the global cellular fraction and
were not found within the RISC in U-87 astrocytoma (p,0.01,
log2 fold change .62.5). Of these global-specific, 32 mRNA were
decreased compared to 12 mRNAs that were increased (Figure 7B).
RISC contained less mRNAs than the global cellular fraction and
specifically contained 15 decreased mRNAs and 7 increased
mRNAs (Figure 7B). Common to both fractions were 5 decreased
mRNAs and 6 increased mRNAs (Figure 7B).
Significant (p,0.01) mRNA levels with a log2 fold change
.62.5 in RISC and in the global cellular milieu of U-87
astrocytoma cells as compared to primary astrocytes were assessed
using IPA for their predicted association with various diseases or
disorders (Figure 8) and their predicted role in molecular and
cellular functions (Figure 9). RISC were more highly enriched in
mRNA involved in cancer, inflammatory, immunological and
neurological disorders, among others (Figure 8). In comparison,
the global cellular fraction was more highly enriched with mRNA
that are involved in infectious diseases as well as hematological and
dermatological disorders (Figure 8). U-87 astrocytoma RISC were
more highly enriched in mRNA components that are involved in
multiple cell functions and processes including the cell cycle,
cellular growth and proliferation, DNA replication, DNA
recombination and repair, and cellular assembly and organization,
among others (Figure 9). In comparison, the global cellular
fraction was more highly enriched with mRNA involved in antigen
presentation and amino acid metabolism (Figure 9). Given that
mRNAs important in cell cycle control and cancer are specifically
enriched in the RISC within astrocytoma cells suggests the
possibility that the RISC may be a future target for brain cancer
therapies.
Biological pathway analysis of miRNA and mRNA profile
in U-87 astrocytoma RISC
RISC miRNA and mRNA microarray data was examined using
IPA software to help appreciate the key mRNA-miRNA
connections and biological pathways that were associated directly
with the RISC and GW/P bodies (Figure 10). In this analysis, all
selected miRNA had a fold change .63 and all mRNA had a fold
change .62 (Figure 10). Each mRNA or miRNA was colored
based upon the experimental expression level (i.e. green signified
decreased expression and red specified increased expression) and
the exact log2 fold change values were indicated below the
molecule (Figure 10).
As noted above, miR-34a levels were increased in U-87
astrocytoma RISC compared to primary astrocyte RISC with a
log2 fold change of 3.040 (Figure 3D, Table 1, p-value
8.43610
29). In U-87 astrocytoma RISC, increased miR-34a
levels corresponded specifically with the significantly (p,0.01)
decreased levels of miR-34a predicted targets: claudin 11
(CLDN11*, 22.950), nexilin F actin binding protein (NEXN*,
22.140) and six homeobox 6 (SIX6, 22.040) which have roles in
cell adhesion, permeability, migration and proliferation (Figure 10,
Table 5). MiR-195 expression was also increased in U-87
astrocytoma GW/P bodies compared to primary astrocyte GW/
P bodies with a log2 fold change of 5.468 (Figure 3D, Table 1, p-
value 7.00610
27). Increased miR-195 expression in U-87
astrocytoma RISC correlated with the significantly (p,0.01)
decreased levels of miR-195 predicted targets: Fraser syndrome
1 (FRAS1*, 22.270) and thyrotropin-releasing hormone degrad-
ing enzyme (TRHDE, 22.170), which are involved in in cell
communication and signalling (Figure 10, Table 6). MiR-195 is
also predicted to silence reticulon 1 (RTN1*) which has a role in
apoptosis, however the mRNA microarray results of our study
show that RTN1* levels were increased by a log2 fold change of
2.470 in U-87 astrocytoma RISC, suggesting that miR-195
upregulation may have activated RTN1* (Figure 10, Table 6).
Perhaps as in other cells, miR-195 function may have switched
from repression to activation of target translation depending on
the cell cycle status of astrocytoma cells [31,80,81]. Since U-87
astrocytoma cells rapidly proliferate in culture, it is unlikely that
these cells had arrested and moved into quiescence (Go) thereby
questioning the potential activation role of miR-195. Indeed,
rather than being activated, RTN1* may be stabilized by another
binding protein that would prevent miR-195 from binding to
RTN1* to exert a repressive effect. Recent genome-wide studies
have suggested there are two populations of miRNA, one that
positively correlates with its target mRNAs and others that
negatively correlate with cognate targets [82–84]. Thus, it is
possible that miR-195 may have a dual function depending on the
status of the mRNA target or where the mRNA is localized within
the cell. This ‘ying-yang’ area of miRNA biology remains to be
fully elucidated. Alternatively, RTN1* may not be a bona fide target
of miR-195.
Beyond the 6 mRNAs targeted by miR-34a and miR-195, there
were many mRNAs that were increased and decreased in U-87
astrocytoma RISC that were directly (solid black arrows) or
indirectly (dashed black arrows) connected through another
molecule within the same pathway (Figure 10). Central mRNAs
with decreased expression in which 4 or more other mRNAs
converged included insulin-like growth factor 2 (IGF2, 22.870),
fibulin 1 (FBLN1*, 22.370), thrombospondin 1 (THBS1*,
23.710) and chemokine C-X-C motif ligand 12 (CXCL12*,
22.490) all of which have functions in apoptosis, proliferation and
migration (Figure 10). Central mRNAs with increased expression
in which 4 or more other mRNAs converged included epiregulin
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PLoS ONE | www.plosone.org 15 October 2010 | Volume 5 | Issue 10 | e13445Figure 10. Biological pathway analysis showing the links between miRNA and mRNAs IP from RISC of U-87 astrocytoma cells
compared to primary astrocytes using IPA software. All miRNA and mRNA were significantly expressed (p,0.01). MiRNA had a log2 fold
change .3 and mRNA had a log2 fold change .2. Some key canonical pathways are indicated by labels.
doi:10.1371/journal.pone.0013445.g010
Table 5. Specific messenger RNA fold change linked to the increased levels of miR-34a in U-87 astrocytoma RISC.
Name
Entrez gene
name
Fold
Change Role in cell
Canonical pathway/
Biological process Entrez gene summary
CLDN11 claudin 11 22.950 adhesion,
permeability,
sealing in,
formation, migration,
proliferation, sealing
leukocyte extravasation
signaling, tight junction
signaling, cell adhesion,
spermatogenesis, axon
ensheathment, calcium-
independent cell-cell
adhesion
The protein encoded by this gene belongs to the claudin
family of tight junction associated proteins and is a major
component of central nervous system myelin that is
necessary for normal CNS function. There is growing
evidence that the protein determines the permeability
between layers of myelin sheaths via focal adhesion and,
with its expression highly regulated during development,
may play an important role in cellular proliferation and
migration. In addition, the protein is a candidate
autoantigen in the development of autoimmune
demyelinating disease.
NEXN nexilin (F actin
binding protein)
22.140 migration regulation of cell migration,
regulation of cytoskeleton
organization
NEXN is a filamentous actin (F-actin)-binding protein that
localizes to focal contacts and may be involved in cell
adhesion and migration (Ohtsuka et al., 1998 [PubMed
9832551]; Wang et al., 2005 [PubMed 15823560]).
SIX6 SIX homeobox 6 22.040 proliferation regulation of transcription,
DNA-dependent,
multicellular organism
development, visual
perception, organ
morphogenesis
The protein encoded by this gene is a homeobox protein
that is similar to the Drosophila ‘sine oculis’ gene product.
This gene is found in a cluster of related genes on
chromosome 14 and is thought to be involved in eye
development. Defects in this gene are a cause of isolated
microphthalmia with cataract type 2 (MCOPCT2).
doi:10.1371/journal.pone.0013445.t005
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chemokine C-X-C motif ligand 2 (CXCL2, 2.250), interleukin 1
alpha (IL1A*, 2.340), interleukin 1 beta (IL1B*, 2.440), interleukin
1 receptor antagonist (IL1RN*, 2.280), tumor necrosis factor alpha
induced protein factor 6 (TNFAIP6, 2.000), transforming growth
factor alpha (TGFA*, 2.660), prostaglandin-endoperoxide syn-
thase 2 (PTGS2*, 2.530), matrix metallopeptidase 3 (MMP3,
2.770) and matrix metallopeptidase 12 (MMP12, 2.340) which
have functions in apoptosis, migration, proliferation and invasion
(Figure 10). The mRNAs that are involved in key canonical
pathways are indicated by labels and include Systemic Lupus
Erythematosus signalling, p38 MAPK signalling, clathrin-mediat-
ed endocytosis signalling, pathogenesis of multiple sclerosis and
others (Figure 10). The majority (.90%) of these mRNAs
localized to U-87 astrocytoma RISC are associated with
tumorigenesis and cancer (label not shown on biological pathway
to avoid figure crowding), which suggests the miRNA-loaded
RISC is a key regulator of mRNAs involved in cancer and cell
cycle regulation in U-87 astrocytoma cells.
The hypothesis was the RISC-specific miRNA and mRNA
components will not only differ between malignant and non-
malignant cells of the same cell lineage, but will also differ between
cells originating from different organs. In this study, evidence is
provided that RISC contains miRNA and mRNA species whose
levels are increased or decreased compared to the global cellular
miRNA and mRNA levels and differ in miRNA and mRNA
composition between cell types, although the overall functional
impact of these differences remains to be elucidated. In order to go
beyond reporting log2 values of various miRNA and mRNA
species within GW/P bodies/RISC compared to the whole cell
fraction for the two human cell types used, our study employed the
use of IPA software to contextualize the dataset in terms of disease
and molecular pathways. Limitations of IPA analysis of microarray
data are acknowledged and other interpretations and conclusions
with respect to our data are possible. Nevertheless, IPA remains a
useful method to assign disease/pathway relevance to multiple
miRNA and mRNA species across cell lines and from multiple
experiments without endeavouring to perform time- and cost-
intensive functional analysis on an individual miRNA or mRNA.
The IPA predicted targets and specific functions of mRNA and
miRNAs within the RISC must be validated by in vitro or in vivo
functional studies.
In this study, the GW/P body/RISC protein complex was
immunoprecipitated using the well-documented and widely used
GW/P body prototype human serum (18033) containing antibod-
ies to GW182 and hAgo2. The human serum used for IP has been
documented to contain GW182 antibodies but did not contain
antibodies to the other GW family members, GW2 and GW3. In
addition, being a polyclonal serum, 18033 also contains antibodies
to hAgo2 but there is no evidence that it targets Ago1, Ago3 or
Ago4. However, at least two reports have shown that antibodies to
Ago2 are generally cross-reactive with other Argonaute proteins
(1, 3 and 4) most likely because they have ,90% sequence
homology [85,86]. This suggests that 18033 may also cross-
immunoprecipitate Ago1, Ago3 and Ago4 proteins. Thus, in
addition to Ago2, the data derived in our experiments likely
encompassed extensive heterogeneity of Ago components believed
to be embedded in the RISC.
The current study provides a methodological framework that
produced a set of unique profiles from human primary astrocytes
and U-87 astrocytoma cells in which to start building the RISC-
miRNA and RISC-mRNA component repository. Further RISC
and GW/P body RNA component profiling is required.
Supporting Information
Figure S1 Global versus RISC-IP miRNA probe reporter signal
intensity for (A) U-87 astrocytoma cells and (B) primary human
astrocytes.
Found at: doi:10.1371/journal.pone.0013445.s001 (2.88 MB TIF)
Figure S2 Global miRNA expression in human U-87 astrocy-
toma cells compared to primary human astrocytes.
Found at: doi:10.1371/journal.pone.0013445.s002 (2.14 MB TIF)
Figure S3 Hierarchical cluster heatmap of significant mRNA
expression in primary astrocytes and U-87 astrocytoma cells
Table 6. Specific messenger RNA fold change linked to increased levels of miR-195 in U-87 astrocytoma RISC.
Name Entrez gene name
Fold
Change Role in cell
Canonical pathway/
Biological process Entrez gene summary
FRAS1 Fraser
syndrome 1
22.270 unknown cell communication This gene encodes an extracellular matrix protein that
appears to function in the regulation of epidermal-
basement membrane adhesion and organogenesis
during development. Mutations in this gene cause Fraser
syndrome, a multisystem malformation that can include
craniofacial, urogenital and respiratory system
abnormalities. Alternative splicing results in multiple
transcript variants.
TRHDE thyrotropin-releasing
hormone degrading
enzyme
22.170 signaling glutathione metabolism,
proteolysis, signal
transduction, cell-cell
signaling
This gene encodes a member of the peptidase M1
family. The encoded protein is an extracellular peptidase
that specifically cleaves and inactivates the neuropeptide
thyrotropin-releasing hormone.
RTN1 reticulon 1 2.470 apoptosis signal transduction, neuron
differentiation
This gene belongs to the family of reticulon encoding
genes. Reticulons are associated with the endoplasmic
reticulum, and are involved in neuroendocrine secretion
or in membrane trafficking in neuroendocrine cells.
Alternatively spliced transcript variants encoding
different isoforms have been identified. Multiple
promoters rather than alternative splicing of internal
exons seem to be involved in this diversity.
doi:10.1371/journal.pone.0013445.t006
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PLoS ONE | www.plosone.org 17 October 2010 | Volume 5 | Issue 10 | e13445isolated from RISC-IP. MRNAs included in the heatmap had a
fold change .2.3 (p,0.01).
Found at: doi:10.1371/journal.pone.0013445.s003 (2.36 MB TIF)
Figure S4 Hierarchical cluster heatmap of significant mRNA
expression in primary astrocytes and U-87 astrocytoma cells
isolated global total RNA samples. MRNAs included in the
heatmap had a fold change .2.3 (p,0.01).
Found at: doi:10.1371/journal.pone.0013445.s004 (0.63 MB TIF)
Table S1 Forward and reverse primers used for validation of
gene expression and miRNA expression by qRT-PCR analysis.
Found at: doi:10.1371/journal.pone.0013445.s005 (0.04 MB
DOC)
Table S2 Global mRNA levels in human U-87 astrocytoma cells
compared to primary human astrocytes with a fold change greater
than 2.3 with p,0.01.
Found at: doi:10.1371/journal.pone.0013445.s006 (0.17 MB
DOC)
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